Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Thermo Fisher Scientific

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces agreement with Thermo Fisher Scientific for fill/finish Manufacturing of Moderna's COVID-19 vaccine.

Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna's COVID-19 Vaccine

Best Buy

Salesforce

Las Vegas Sands

Microsoft

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. And our deep-learning algorithms have identified Best Buy and Salesforce.com among other trending stocks.

Best Buy And Salesforce.com Among Today's Trending Stocks

More than 124 million doses have been administered under an emergency use authorization.

Moderna seeks full FDA approval of its COVID-19 vaccine

If Moderna secures full FDA approval, will vaccine hesitancy fade?

Moderna Inc (NASDAQ:MRNA) is making headlines yet again today, this time after the biotech name said it has applied for full approval for its Covid-19 vaccine, mRNA, from the U.S. Food and Drug Administration (FDA).

Moderna Applies for Full FDA Approval for Covid-19 Vaccine

Moderna on Tuesday asked the Food and Drug Administration for full approval of its COVID-19 vaccine in Americans 18 and older.

Moderna applies for full FDA approval of its COVID-19 vaccine

Moderna asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine.

Moderna applies for full FDA approval of its Covid vaccine

Shares of Moderna Inc. gained 0.1% in premarket on Tuesday after the company said it is formally seeking full approval from the Food and Drug Administration for its COVID-19 vaccine. Moderna said it has initiated a rolling submission to the FDA; the company's shot was the second to receive emergency use authorization in the U.S., back in December.

Moderna submits 'rolling' application as part of process to obtain full FDA approval for its COVID-19 shot

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces initiation of rolling submission of Biologics License Application (BLA) with the U.S. FDA for the Moderna COVID-19 vaccine.

Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine

Moderna's strengths in technology may give it an edge.

Here's How Moderna Plans to Beat the Biggest Threat to Its Vaccine

Intel

Tesla

Pfizer

Canadian Pension Plan Investment Board cut more than three-quarters of positions in chip giant Intel and electric-vehicle maker Tesla, and bought Moderna and Pfizer stock in the first quarter.

Giant Pension Slashed Intel, Tesla Stakes. It Scooped Up Covid-Vaccine Makers.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at upcoming investor conferences in June 2021.

Moderna to Present at Upcoming Investor Conferences in June 2021

The answer is better than you might think.

How are Pfizer's and Moderna's Vaccines Faring Against Coronavirus Variants?

The fight for 2022 COVID-19 vaccine supply will likely take place in Europe and lesser-developed countries.

Moderna: Stuck Between CureVac And A Hard Place

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna highlights advances in platform science and innovative vaccine research at fourth annual Science Day.

Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day

BioNTech SE

Johnson & Johnson

On Tuesday, Reuters reported that the EU is targeting more than 1 billion COVID-19 shots by September. This is a huge figure considering that since the vaccine roll-outs began earlier this year, only 266 million vaccinations have been administered in the European Union.

Best COVID-19 vaccine stock to buy in June: Pfizer

Moderna (MRNA) reports 100% efficacy of its COVID-19 vaccine in teenagers aged 12 to less than 18.

Moderna's (MRNA) COVID-19 Vaccine 100% Effective in Teens

Dyadic International Inc., DE

Novavax

The process of lining up the next wave of vaccines – Vax 2.0 – is likely already underway behind closed doors at major science institutes, throughout top research think-tanks, and at the home bases of the major vaccine-oriented pharma players. Vax 2.0 is no longer a theory.

Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)

This potential market is definitely large enough to motivate drugmakers to go after it.

How Big Is the COVID Vaccine Market for Younger Kids?

Are Pfizer and Moderna Trying to Boost Sales With an Early COVID Booster Shot?

Moderna Inc (NASDAQ: MRNA) expects to launch a single-dose COVID-19 vaccine in India in 2022 and is in talks with Cipla, among other Indian firms, reports Economic Times. While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021.

Moderna Sees Single-Dose COVID-19 Vaccine Launch In India In 2022

The company should submit its request for the FDA to authorize the use of its vaccine in those 12 and older in a couple of weeks.

Moderna's Teen COVID-19 Vaccine Trial Hits High Marks

Moderna Inc (NASDAQ:MRNA) is the second company -- after Pfizer (PFE) -- to develop a Covid-19 vaccine proven to be highly effective in younger age groups.

MRNA Climbs on Upbeat Vaccine Update for Younger Age Groups

Moderna says its COVID-19 vaccine is effective in teenagers

Shares of COVID-19 vaccine maker Moderna Inc (NASDAQ: MRNA) were trading higher by more than 2% Tuesday morning after announcing encouraging results from its TeenCOVE study. Study results Moderna said in a press release its Phase ⅔ study of its COVID-19 vaccine (mRNA-1273) in adolescents met its primary immunogenicity endpoint.

News for Moderna Stock (MRNA)